Ivonescimab Shows Survival Advantage Over Keytruda in Lung Cancer Trial on September 14, 2026 Akeso Antibodies, Bispecific Ivonescimab Keytruda Non-Small Cell Lung Carcinoma non-small-cell lung cancer Overall Survival PD-L1-high pembrolizumab Progression-Free Survival +